Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulopenem versus ertapenem-based therapy for complicated intra-abdominal infection in adults
2017-003773-34Phase 3Completed
- Sponsor
- Iterum Therapeutics plc
- Start
- Sep 2018
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sulopenem and ertapenem in Intra-abdominal infection (IAI) (2 arms), sponsored by Iterum Therapeutics plc. Primary endpoint: Primary efficacy endpoint. Started Sep 2018; status: completed.
02
Drugs
sulopenemertapenem
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on 2017-003773-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003773-34.